While infigratinib suppressed the growth of the HCC21-0208 tumour overexpressing EZH2, the tumour inhibition was less than that of the control vector tumour, as suggested by the difference in tumour burden over time (Fig. 3C). Here, EZH2 is linked to neoplasm.